Lee Rubin named HSCI co‑director

Harvard’s appointment of Lee Rubin as faculty co-director of the Harvard Stem Cell Institute is more than a routine leadership change. Rubin is not an administrator imported from outside the field; he is a stem-cell and regenerative biology professor whose research has centered on neurodegenerative disease, patient-derived cell models and the development of therapies. (harvardmagazine.com) Effective this spring, he will serve alongside David Scadden, succeeding HSCI co-founder Doug Melton. ### Who is Lee Rubin in Harvard’s research ecosystem? Lee Rubin is a professor of stem cell and regenerative biology at Harvard and has been involved with HSCI since it began, according to Harvard Magazine and university statements. His research focuses on neurodegenerative diseases including Parkinson’s disease, ALS and spinal muscular atrophy, and on using stem cells to model disease in ways that could support drug discovery and treatment development. (harvardmagazine.com) Rubin joined Harvard in 2006 after work in both academia and industry. Harvard Magazine said his career included roles at Athena Neurosciences, University College London, Eisai London Laboratories and Curis, and noted that work tied to the blood-brain barrier contributed to development of the multiple sclerosis drug Tysabri. (harvardmagazine.com) ### Why does his scientific background matter for HSCI? David Scadden, the institute’s continuing co-director, framed Rubin’s appointment around HSCI’s current priorities. Scadden said Rubin was joining at “a particularly important time” as the institute continues moving discoveries toward clinical application and places greater emphasis on aging-related conditions. (harvardmagazine.com) That makes Rubin’s background notable because his lab has focused on how aging and disease alter the nervous system. Harvard Magazine said his group uses stem cells to produce patient-specific neurons and study how illnesses begin and develop, with the aim of identifying therapies that could improve patient function. (harvardmagazine.com) ### What changes at the institute’s top table? Rubin will serve with Scadden, the Jordan Professor of Medicine and professor of stem cell and regenerative biology at Harvard. He replaces Doug Melton, the Xander University Professor who co-founded HSCI in 2005 and had remained a central figure in the institute’s leadership. (harvardmagazine.com) HSCI was founded in 2005 and is described by Harvard as a network of hundreds of scientists and faculty members across Harvard and its affiliated institutions. Its research spans cancers, diabetes, blood and cardiovascular disease, skin disease and other areas where stem-cell science is being applied to medicine. (harvardmagazine.com) ### What does Rubin say he wants to do in the role? Rubin said in a university statement that he had been involved with HSCI “from the moment it started” and was excited to help Scadden continue the work of investigators pursuing both research and new therapeutics. That language places his emphasis on translational science — research designed not only to explain disease but also to produce treatments. (harvardmagazine.com) Harvard Magazine also noted that Rubin serves as faculty co-chair of the M.S./M.B.A. Biotechnology: Life Sciences dual master’s program run by the Faculty of Arts and Sciences and Harvard Business School. That role adds to the picture of a scientist whose work sits across basic biology, commercialization and therapeutic development. (harvardmagazine.com) ### Why are people on campus likely to watch this appointment closely? The May 19 announcement comes at a time when HSCI is still defined by its cross-school, cross-hospital structure and by pressure to translate stem-cell discoveries into therapies. Scadden’s statement tied Rubin’s arrival directly to that push toward clinical application and aging-related research, giving the clearest available explanation of what Harvard sees as the institute’s immediate agenda. (harvardmagazine.com) For students and researchers, the practical significance will likely show up in future institute programming, disease-area emphasis and collaborations, though Harvard’s announcement did not lay out a new strategic plan. The next concrete step is already set: Rubin begins as co-director this spring alongside Scadden, leading an institute founded in 2005 and spanning hundreds of investigators across Harvard. (harvardmagazine.com)